SCHEMBL3967275

SCHEMBL3967275

Cc1cc(Nc2cc3ccccc3c(Sc3cccc(Cl)c3)n2)n[nH]1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 16/20 0.62
▸ GSK3B P49841 9/20 0.62
▸ AURKB Q96GD4 7/20 0.62
▸ SRC P12931 3/20 0.48
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ NTRK1 P04629 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ PAK4 O96013 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SYK P43405 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967880 0.89 AURKA (0.61) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3969294 0.89 AURKA (0.49) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3967338 0.89 AURKA (0.59) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3971284 0.87 AURKA (0.50) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3968692 0.86 AURKA (0.52) AURKAGSK3BAURKBSRCPLK4
SCHEMBL3965326 0.85 AURKA (0.50) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3961786 0.84 AURKA (0.51) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3968221 0.82 AURKA (0.61) AURKAGSK3BAURKBSRCNTRK1
SCHEMBL3961607 0.82 AURKA (0.52) AURKAGSK3BAURKBSRCCYP1A2
SCHEMBL3961657 0.79 AURKA (0.50) AURKAGSK3BAURKBSRCNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 — — US claimed
EP-1966190-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 — — EP claimed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 — — US claimed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 — — WO claimed
US-7572809-B2 Isoquinoline aminopyrazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-08-11 — — US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 AURKA 1165/4885GSK3B 842/4885AURKB 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback